Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences has launched Semaglutide Injection in India under three brand names — SEMAGLYN, MASHEMA and ALTERME — following patent expiry. The product, a GLP-1 therapy approved by the DCGI, is meant for treating Type 2 Diabetes and Obesity. It will be sold as a 15mg/3ml prefilled cartridge used with an innovative reusable multi-dose pen device, for which Zydus holds exclusive rights, manufactured at its Ahmedabad Biotech Park. The average monthly cost of treatment is approximately Rs. 2,200, significantly lower than buying multiple single-dose pens. The launch targets a large domestic market, with 8.9 crore Indian adults living with diabetes and obesity prevalence rising sharply across both men and women.
This strengthens Zydus's domestic portfolio in the fast-growing GLP-1 segment and could drive incremental revenue given the large patient pool and affordable pricing. However, the stock impact may be muted as other generic players are likely to enter the market post patent expiry, intensifying competition.